by jmanor | Aug 3, 2022 | White Papers
This paper reviews the evidence covering the impact of biopharmaceuticals on the level and growth of total health care costs. The primary source of spending in health care is on labor, such as doctors, nurses or assistants, which makes up over 70% of overall spending,...
by susuguo | Jul 1, 2022 | White Papers
In theory, equilibrium profits for drug patent holders would not involve significant restraints on production and patient utilization if the market had a mechanism for two-part pricing (Oi 1971) or quantity commitments (Murphy, Snyder, and Topel 2014). In fact, patent...
by jmanor | Jun 27, 2022 | White Papers
In February 2022, the Biden Administration aimed to reignite the Cancer Moonshot through its proposed federal budget and stated that one of its objectives is to reduce cancer mortality by 50% over the next 25 years. Currently, there is already a very large amount of...
by jmanor | May 16, 2022 | White Papers
There exists a large scientific literature on the value of improved health and how to incorporate that value into policy and decision making where activities impact health outcomes. The purpose of this policy brief is to review literature on the value of health in...
by susuguo | Apr 1, 2022 | White Papers
Almost exactly two years ago COVID-19 spread to the United States. Following the federalism model, the 50 states and their governors and legislators made many of their own pandemic policy choices to mitigate the damage from the virus. States learned from one another...
by susuguo | Feb 1, 2022 | White Papers
Marginal prices fell, and disposable incomes increased, for drug and alcohol consumers during the pandemic. Most of the amount, timing, and composition of the 240,000 deaths involving alcohol and drugs since early 2020 can be explained by income effects and...
